Sunshine Biopharma (NASDAQ:SBFM) announced that it has signed an agreement to market two new generic antibiotics in Canada through its wholly owned Canadian subsidiary, Nora Pharma, subject to regulatory approval.
According Sunshine, it anticipates launching these new products in the next six to nine months. The company has 70 generic prescription drugs currently on the Canadian market, with 13 additional drugs scheduled for launch in 2025.
Dr. Steve Slilaty, CEO of Sunshine, commented, “We believe we are strategically positioned, through Nora Pharma, to introduce these two new antibiotics to the market, complementing our existing portfolio of 70 generic prescription drugs currently on the market in Canada. This expansion signifies a pivotal step in our mission to advance healthcare solutions for our patients.”
